Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
REVLIMID (Celgene Pty Ltd)
Product name
REVLIMID
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
162 working days (255)
Active ingredients
lenalidomide
Registration type
EOI
Indication
REVLIMID is now also indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.